3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer

Pfizer is being pitched as an income play with a 6.7% dividend yield and a forward P/E of 8.7 (five‑year avg 9.7) while pursuing growth via a GLP‑1 licensing deal with YaoPharma and oncology investments, though management cautions a turnaround may not occur in 2026. Western Union offers a 10.14% dividend yield and a 17% total shareholder yield, reported flat Q3 revenue but improved operating margins to 20% and 49% YoY growth in consumer services, and is developing a stablecoin/digital money-transfer network; forward P/E is 5.3 (five‑year avg 7.3). The Schwab U.S. Dividend Equity ETF (SCHD) yields ~3.8% with a 10‑year average annual gain of 2.9% and exposure to dividend-growers such as Lockheed Martin, Bristol‑Myers Squibb and Chevron.

Analysis

Market structure: Pfizer (PFE) and legacy dividend names win short-term investor income needs — PFE's 6.7% yield and forward P/E 8.7 (vs 5‑yr avg 9.7) implies ~11% multiple upside if sentiment normalizes; Western Union (WU) offers cyclical income (10% yield, 17% shareholder yield) but its stablecoin pivot shifts competitive dynamics toward payments rails and crypto custody incumbents, pressuring margins for small remitters. Supply/demand: GLP‑1/oncology licensing increases future drug supply risk (higher development spend → later revenue concentration) while remittance crypto usage could compress fee supply for incumbents; FX volatility will matter more for WU revenue flows.

Risk assessment: Tail risks include GLP‑1/oncology trial failures or YaoPharma regulatory denial (10–30% chance over 12–24 months), and severe regulatory action on stablecoins (20% probability of restrictive US rules in 6–12 months) that could erase WU’s fintech upside and trigger dividend cut. Immediate (days) sensitivity: earnings/FX headlines; short-term (weeks–months): Q1/Q2 results and regulatory signals; long-term (quarters–years): pipeline approvals and stablecoin adoption. Hidden dependencies: WU’s payouts are FX- and volume-dependent; PFE’s dividend sustainability depends on cash flow post-COVID franchise decline and buyback cadence.

Trade implications: Favor a measured value-income stance: establish small long core positions in PFE and SCHD while using options to hedge trial/regulatory binary risk. Use pair trades to reduce idiosyncratic risk (long PFE or SCHD vs short high‑beta small-cap biotech or non-dividend fintech names). For WU, prefer income strategies (covered calls/cash‑secured puts) rather than naked directional exposure given regulatory tail risk.

Contrarian angles: Market may underprice PFE’s pipeline optionality — a single oncology success could double upside beyond multiple reversion; conversely, market may overrate WU’s stablecoin pathway — regulatory, AML, and bank-rail resistance make rapid revenue substitution unlikely. Historical parallel: money‑transfer incumbents (Western Union vs digital entrants) show slow share shifts; expect multi-year transition, not instant disruption. Unintended consequence: WU’s crypto push could provoke capital‑intensive compliance costs and compress free cash flow, risking dividend sustainability.

Key Decisions for Investors

• Establish a 2–3% long position in PFE (buy stock) within 30 days targeting total return 15–25% over 12–24 months (assume ~6.7% dividend + ~8–18% price upside if P/E reverts to 9.7–11.0); hedge by buying 6‑month 10% OTM puts sized to protect 50% of the position or sell 1–3 month covered calls to monetize yield if comfortable capping upside.
• Allocate 3–5% to SCHD as core dividend exposure immediately to reduce single‑name risk; rebalance if SCHD outperforms by >8% or if 12‑month trailing yield falls below 3.2%.
• For WU, do not take naked long exposure: sell cash‑secured puts 10–15% below current price with 60–120 day expiries to collect premium and set a conservative entry; alternatively sell 30–90 day covered calls at ~10% OTM to capture income while limiting upside, maintaining position size at 1–2% of portfolio.
• Implement one relative trade: long PFE (2%) vs short a small‑cap biotech ETF (1–1.5%) to offset binary trial risk; target pair horizon 6–12 months and close if PFE outperforms by >20% or biotech shorts fall <‑25%.
• Monitor within 30–90 days: FDA/clinical readouts for PFE pipeline and US stablecoin regulatory announcements (Treasury/SEC/FSB guidance). If PFE misses a major approval or WU receives adverse regulatory guidance, reduce respective positions by 50% within 5 trading days.